التفاصيل البيبلوغرافية
| العنوان: |
CNS prophylaxis in lymphoma: Who to target and what therapy to use. |
| المؤلفون: |
Hill, Quentin A., Owen, Roger G. |
| المصدر: |
Blood Reviews; Nov2006, Vol. 20 Issue 6, p319-332, 14p |
| مصطلحات موضوعية: |
LYMPHOMAS, CENTRAL nervous system, BURKITT'S lymphoma, LYMPHOBLASTIC leukemia, LYMPHOPROLIFERATIVE disorders, B cells |
| مستخلص: |
Summary: The purpose of this article is to review the current data on the risk of CNS relapse in patients with lymphoma and the efficacy of CNS directed prophylactic therapy. CNS relapse occurred in 30–50% of those with Burkitt lymphoma and acute lymphoblastic leukaemia/lymphoma prior to the introduction of intensified regimens that include CNS prophylaxis. Most patients with AIDS-related-lymphoma receive a short course of intrathecal prophylaxis but a re-evaluation of type and targeting of CNS prophylaxis is needed. Patients with diffuse large B-cell lymphoma (DLBCL) have a 5% overall risk of CNS relapse but a high risk sub-population can be identified on the basis of raised LDH and >1 extranodal site, testicular or primary breast involvement. CNS prophylaxis for selected patients with DLBCL may be justified by risk but its benefit is not yet proven. Intravenous methotrexate ⩾3 g/m2 achieves therapeutic levels in CSF and parenchyma and in combination with intrathecal methotrexate would be a reasonable option for prophylaxis. [Copyright &y& Elsevier] |
|
Copyright of Blood Reviews is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Supplemental Index |
